211 related articles for article (PubMed ID: 27931829)
1. Primary immunodeficiencies associated with EBV-Induced lymphoproliferative disorders.
Shabani M; Nichols KE; Rezaei N
Crit Rev Oncol Hematol; 2016 Dec; 108():109-127. PubMed ID: 27931829
[TBL] [Abstract][Full Text] [Related]
2. Inherited Immunodeficiencies With High Predisposition to Epstein-Barr Virus-Driven Lymphoproliferative Diseases.
Latour S; Winter S
Front Immunol; 2018; 9():1103. PubMed ID: 29942301
[TBL] [Abstract][Full Text] [Related]
3. Advances in Understanding the Pathogenesis of Epstein-Barr Virus-Associated Lymphoproliferative Disorders.
Yang X; Nishida N; Zhao X; Kanegane H
Iran J Allergy Asthma Immunol; 2015 Oct; 14(5):462-71. PubMed ID: 26742434
[TBL] [Abstract][Full Text] [Related]
4. Primary immunodeficiencies predisposed to Epstein-Barr virus-driven haematological diseases.
Parvaneh N; Filipovich AH; Borkhardt A
Br J Haematol; 2013 Sep; 162(5):573-86. PubMed ID: 23758097
[TBL] [Abstract][Full Text] [Related]
5. Association of Epstein-Barr virus with regression after withdrawal of immunosuppressive drugs and subsequent progression of iatrogenic immunodeficiency-associated lymphoproliferative disorders in patients with autoimmune diseases.
Fujimoto K; Hatanaka KC; Hatanaka Y; Kasahara I; Yamamoto S; Tsuji T; Nakata M; Takakuwa Y; Haseyama Y; Oyamada Y; Yonezumi M; Suzuki H; Sakai H; Noguchi H; Mori A; Nishihara H; Teshima T; Matsuno Y
Hematol Oncol; 2020 Dec; 38(5):799-807. PubMed ID: 32798315
[TBL] [Abstract][Full Text] [Related]
6. Senile Epstein-Barr virus-associated B-cell lymphoproliferative disorders: a mini review.
Shimoyama Y; Oyama T; Asano N; Oshiro A; Suzuki R; Kagami Y; Morishima Y; Nakamura S
J Clin Exp Hematop; 2006 Mar; 46(1):1-4. PubMed ID: 17058802
[TBL] [Abstract][Full Text] [Related]
7. Lymphoproliferative disorders in children with primary immunodeficiencies: immunological status may be more predictive of the outcome than other criteria.
Canioni D; Jabado N; MacIntyre E; Patey N; Emile JF; Brousse N
Histopathology; 2001 Feb; 38(2):146-59. PubMed ID: 11207828
[TBL] [Abstract][Full Text] [Related]
8. Advanced therapeutic and prophylactic strategies for Epstein-Barr virus infection in immunocompromised patients.
Okano M; Gross TG
Expert Rev Anti Infect Ther; 2007 Jun; 5(3):403-13. PubMed ID: 17547505
[TBL] [Abstract][Full Text] [Related]
9. [Diagnosis and management of EBV-positive lymphoproliferative disorders].
Arai A
Rinsho Ketsueki; 2023; 64(8):764-771. PubMed ID: 37673629
[TBL] [Abstract][Full Text] [Related]
10. Severe Epstein-Barr virus infection in primary immunodeficiency and the normal host.
Worth AJ; Houldcroft CJ; Booth C
Br J Haematol; 2016 Nov; 175(4):559-576. PubMed ID: 27748521
[TBL] [Abstract][Full Text] [Related]
11. [Inherited lymphoproliferative disorders].
Kanegane H; Hoshino A
Rinsho Ketsueki; 2019; 60(6):708-715. PubMed ID: 31281164
[TBL] [Abstract][Full Text] [Related]
12. Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal?
Natkunam Y; Gratzinger D; Chadburn A; Goodlad JR; Chan JKC; Said J; Jaffe ES; de Jong D
Blood; 2018 Nov; 132(18):1871-1878. PubMed ID: 30082493
[TBL] [Abstract][Full Text] [Related]
13. Plasmacytic hyperplasia in age-related Epstein-Barr virus-associated lymphoproliferative disorders: a report of two cases.
Kojima M; Morita Y; Nakamura N; Shimizu K; Murayama K; Nakamura S
Pathol Res Pract; 2008; 204(4):267-72. PubMed ID: 18187262
[TBL] [Abstract][Full Text] [Related]
14. [EBV and immunodeficiency].
Dieudonne Y; Martin M; Korganow AS; Boutboul D; Guffroy A
Rev Med Interne; 2021 Dec; 42(12):832-843. PubMed ID: 33867195
[TBL] [Abstract][Full Text] [Related]
15. Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target.
Tse E; Kwong YL
Exp Mol Med; 2015 Jan; 47(1):e136. PubMed ID: 25613733
[TBL] [Abstract][Full Text] [Related]
16. Cancer Therapy-associated Lymphoproliferative Disorders: An Under-recognized Type of Immunodeficiency-associated Lymphoproliferative Disorder.
Pina-Oviedo S; Miranda RN; Medeiros LJ
Am J Surg Pathol; 2018 Jan; 42(1):116-129. PubMed ID: 29112013
[TBL] [Abstract][Full Text] [Related]
17. Documentation of Epstein-Barr virus infection in immunodeficient patients with life-threatening lymphoproliferative diseases by Epstein-Barr virus complementary RNA/DNA and viral DNA/DNA hybridization.
Saemundsen AK; Purtilo DT; Sakamoto K; Sullivan JL; Synnerholm AC; Hanto D; Simmons R; Anvret M; Collins R; Klein G
Cancer Res; 1981 Nov; 41(11 Pt 1):4237-42. PubMed ID: 6272968
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008.
Cohen JI; Kimura H; Nakamura S; Ko YH; Jaffe ES
Ann Oncol; 2009 Sep; 20(9):1472-1482. PubMed ID: 19515747
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive molecular diagnosis of Epstein-Barr virus-associated lymphoproliferative diseases using next-generation sequencing.
Ono S; Nakayama M; Kanegane H; Hoshino A; Shimodera S; Shibata H; Fujino H; Fujino T; Yunomae Y; Okano T; Yamashita M; Yasumi T; Izawa K; Takagi M; Imai K; Zhang K; Marsh R; Picard C; Latour S; Ohara O; Morio T
Int J Hematol; 2018 Sep; 108(3):319-328. PubMed ID: 29777376
[TBL] [Abstract][Full Text] [Related]
20. Genetic susceptibility to EBV infection: insights from inborn errors of immunity.
Tangye SG
Hum Genet; 2020 Jun; 139(6-7):885-901. PubMed ID: 32152698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
